All In Biotech

Drug Trial Radar · NCT07444814

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

A Phase 1 First-in-Human Study of PTK7-Directed Antibody Drug Conjugate HWK-007 in Participants With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

226

Planned (sponsor's estimate)

Start

Dec 19, 2025

Primary completion

Sep 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Whitehawk Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.

Conditions

  • Endometrial Cancer
  • Ovarian Cancer
  • Ovarian Cancer Metastatic
  • Ovarian Cancer Metastatic Recurrent
  • Non-squamous EGFR Wt NSCLC
  • Platinum Resistant Ovarian Cancer
  • PROC

Interventions

  • HWK-007Drug

    HWK-007 is a PTK7- targeted ADC being developed for the treatment of solid tumors.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine Maximum Tolerated Dose (MTD)Time frame: From Cycle 1, Day 1 until Cycle 1, Day 21 (21-day cycles)
  2. Determine Maximum Administered Dose (MAD)Time frame: From Cycle 1, Day 1 to Cycle 1, Day 21 (21-day cycles)
  3. Determine the Recommended Dose for Expansion (RDE)Time frame: From Cycle 1, Day 1 to Cycle 1, Day 21 (21-day cycles) until MTD or MAD is identified.
  4. Determination of Recommended Phase 2 Dose (RP2D) (Phase 1b)Time frame: From Cycle 1 Day 1 to End of Primary Completion

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama · Recruiting

  • University of Arizona Cancer Center

    Tucson, Arizona · Recruiting

  • University of Arkansas

    Little Rock, Arkansas · Recruiting

  • UCLA - Hematology/Oncology Clinical Research Unit

    Los Angeles, California · Recruiting

  • Stanford Cancer Institute, Stanford University

    Palo Alto, California · Recruiting

  • St. Francis Medical Center (OSF Healthcare)

    Peoria, Illinois · Recruiting

  • University of Maryland

    Baltimore, Maryland · Recruiting

  • START - Midwest

    Grand Rapids, Michigan · Recruiting

  • Hackensack University Medical Center - John Theurer Cancer Center

    Hackensack, New Jersey · Recruiting

  • Roswell Park Comprehensive Care Center

    Buffalo, New York · Recruiting

  • University Hospital - Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • NEXT Oncology - Austin

    Austin, Texas · Recruiting

  • NEXT - Oncology - Houston

    Houston, Texas · Recruiting

  • START - San Antonio

    San Antonio, Texas · Recruiting

  • NEXT Oncology - Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.